Top Markets
Coin of the day
Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

SPPI
株式のランク #21095
Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily... Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia. Also under development is Poziotinib, a distinct irreversible tyrosine kinase inhibitor intended for non-small cell lung cancer tumors exhibiting various mutations. Furthermore, Anti-CD20-IFNa, an antibody-interferon fusion molecule targeting CD20, is progressing through Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. The company maintains key collaborative agreements, such as co-development, commercialization, and in-licensing arrangements with Hanmi Pharmaceutical Co. Ltd., a patent and technology license with The University of Texas M.D. Anderson Cancer Center, and an in-license pact with ImmunGene, Inc. Founded in 1987, and initially known as NeoTherapeutics, Inc. before its name change in December 2002, Spectrum Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
株価
$1.03
最終同期: 2023-07-31
時価総額
$115.13M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Spectrum Pharmaceuticals, Inc. (SPPI)

カテゴリー

Spectrum Pharmaceuticals, Inc.(SPPI)の配当利回りの履歴
Spectrum Pharmaceuticals, Inc.(銘柄コード: SPPI)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Spectrum Pharmaceuticals, Inc.(SPPI)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)